

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
24 January 2002 (24.01.2002)

PCT

(10) International Publication Number
WO 02/06288 A1

(51) International Patent Classification⁷: **C07D 495/04**,
513/04, 487/04, A61K 31/55, A61P 25/00 // (C07D
495/04, 333:00, 223:00) (C07D 513/04, 277:00, 223:00)
(C07D 487/04, 239:00, 223:00)

(74) Agent: **WAECHTER, Dieter**; Grenzacherstrasse 124,
CH-4070 Basle (CH).

(21) International Application Number: PCT/EP01/08186

(22) International Filing Date: 16 July 2001 (16.07.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
00115450.9 18 July 2000 (18.07.2000) EP

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK,
SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,
IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF,
CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

(71) Applicant: **F.HOFFMANN-LA ROCHE AG** [CH/CH];
Grenzacherstrasse 124, CH-4070 Basle (CH).


Published:

- with international search report
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments

(72) Inventors: **BINGGELI, Alfred**; Im Kugelfang 50,
CH-4102 Binningen (CH). **MAERKI, Hans-Peter**;
Seltisbergerstrasse 75, CH-4059 Basel (CH). **MUTEL,**
Vincent; 15, place des Maréchaux, F-68100 Mulhouse
(FR). **WOSTL, Wolfgang**; Im Strick 2, 79639 Gren-
zach-Wyhlen (DE). **WILHELM, Maurice**; 11, chemin du
Luegner, F-68790 Morschwiller la Bas (FR).

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: TETRAHYDRO-HETEROCYCLOAZEPINYL PYRIMIDINE DERIVATIVES




(57) Abstract: The invention relates to compounds of the general formula (I) wherein HET and R¹ to R¹² have the significances as defined in the specification, as well as their pharmaceutically acceptable salts. The invention further relates to medicaments containing such compounds and a process for the preparation of such compounds. The compounds of formula (I) are group (I) mGluR antagonists and are therefore useful for the control or prevention of acute and/or chronic neurological disorders.

WO 02/06288 A1

Tetrahydro-heterocycloazepinyl pyrimidine derivatives


The present invention is concerned with nitro- and cyano-1,2,4,5-tetrahydro-heterocycloazepinyl pyrimidine derivatives of the general formula



I


wherein

- 5 R^1 signifies oxygen, hydroxy, lower alkoxy or 2,2,2-trifluoroethoxy;
- R^2 signifies nitro or cyano;
- R^3 signifies hydrogen, lower alkyl, oxygen, lower alkoxy, amino, lower alkyl-
amino or hydroxy-lower alkyl-amino;
- R^4 signifies hydrogen, lower alkyl, lower alkenyl,
10 or is absent, if the adjacent nitrogen atom already is the origin of three
bonds as $-N=$ or $=N-$;
- R^5, R^6, R^9 and R^{10} signify, independently from each other, hydrogen or lower alkyl;




signifies


- 2 -




or



or



or

R⁷, R⁸, R¹¹ or R¹²

signify, independently from each other, hydrogen, lower alkyl, or hydroxy;

R¹³ and R¹⁴

signify, independently from each other, hydrogen or lower alkyl;

5 R¹⁵ and R¹⁶

signify, independently from each other, hydrogen or lower alkyl;

R¹⁷

signifies hydrogen, lower alkyl, lower alkoxy, hydroxy or amino;

R¹⁸

signifies hydrogen or hydroxy;

R¹⁹

signifies hydrogen, lower alkyl, lower alkoxy, hydroxy or amino;

V

signifies NH, S or O; and

10 the dotted line may be a bond,

as well as with their pharmaceutically acceptable salts in their racemic and optically active form.

It has surprisingly been found that the compounds of general formula I are antagonists at metabotropic glutamate receptors.

In the central nervous system (CNS) the transmission of stimuli takes place by the interaction of a neurotransmitter sent out by a neuron, with another neuroreceptor.

L-glutamic acid, the most commonly occurring neurotransmitter in the CNS, plays a critical role in a large number of physiological processes. The glutamate-dependent
5 stimulus receptors are divided into two main groups. The first main group forms ligand-controlled ion channels. The metabotropic glutamate receptors (mGluR) belong to the second main group and, furthermore, belong to the family of G-protein-coupled receptors.

At present, eight different members of these mGluRs are known and some of these even have sub-types. On the basis of structural parameters, the different second messenger
10 signaling pathways and their different affinity to low-molecular weight chemical compounds, these eight receptors can be sub-divided into three sub-groups:

mGluR1 and mGluR5 belong to group I, mGluR2 and mGluR3 belong to group II and mGluR4, mGluR6, mGluR7 and mGluR8 belong to group III.

Ligands of metabotropic glutamate receptors belonging to the first group can be used
15 for the treatment or prevention of acute and/or chronic neurological disorders such as epilepsy, stroke, chronic and acute pain, psychosis, schizophrenia, Alzheimer's disease, cognitive disorders and memory deficits.

Other treatable indications in this connection are restricted brain function caused by bypass operations or transplants, poor blood supply to the brain, spinal cord injuries, head
20 injuries, hypoxia caused by pregnancy, cardiac arrest and hypoglycaemia. Further treatable indications are Huntington's chorea, amyotrophic lateral sclerosis (ALS), dementia caused by AIDS, eye injuries, retinopathy, idiopathic parkinsonism or parkinsonism caused by medicaments as well as conditions which lead to glutamate-deficiency functions, such as e.g. muscle spasms, convulsions, migraine, urinary incontinence, nicotine addiction, opiate
25 addiction, psychoses, anxiety, vomiting, dyskinesia and depression.

Objects of the present invention are compounds of formula I and their pharmaceutically acceptable salts per se and as pharmaceutically active substances, their manufacture, medicaments based on a compound in accordance with the invention and their production as well as the use of the compounds in accordance with the invention in
30 the control or prevention of illnesses of the aforementioned kind, and, respectively, for the production of corresponding medicaments. Furthermore, the use of radiolabeled mGluR1

receptor antagonists of formula I in a binding assay is also an object of the present invention.

Preferred compounds of formula I in the scope of the present invention are those, in which R² is NO₂.

5 Further preferred are compounds of formula I in the scope of the present invention, wherein

R¹ is =O or lower alkoxy and

HET represents a thiophene group.

The following are examples of such compounds:

10 [rac]-6-(4-Hydroxy-4,5,7,8-tetrahydro-thieno[2,3-d]azepin-6-yl)-2-methyl-5-nitro-3H-pyrimidin-4-one,

2-Methyl-5-nitro-6-(4,5,7,8-tetrahydro-thieno[2,3-d]azepin-6-yl)-3H-pyrimidin-4-one,

15 6-(6-Ethoxy-2-methyl-5-nitro-pyrimidin-4-yl)-5,6,7,8-tetrahydro-4H-thieno[2,3-d]azepine, or

3-Ethyl-2-methyl-5-nitro-6-(4,5,7,8-tetrahydro-thieno[2,3-d]azepin-6-yl)-3H-pyrimidin-4-one.

Also preferred are compounds of formula I in the scope of the present invention, wherein

20 R¹ is =O or lower alkoxy, and

HET represents a thiazole group.

The following are examples of such compounds:

2-Methyl-6-(2-methyl-4,5,7,8-tetrahydro-thiazolo[4,5-d]azepin-6-yl)-5-nitro-3H-pyrimidin-4-one,

25 6-(6-Ethoxy-2-methyl-5-nitro-pyrimidin-4-yl)-2-methyl-5,6,7,8-tetrahydro-4H-thiazolo[4,5-d]azepine,

3-Ethyl-2-methyl-6-(2-methyl-4,5,7,8-tetrahydro-thiazolo[4,5-d]azepin-6-yl)-5-nitro-3H-pyrimidin-4-one,

30 6-(2-Amino-4,5,7,8-tetrahydro-thiazolo[4,5-d]azepin-6-yl)-2-methyl-5-nitro-3H-pyrimidin-4-one,

6-(2-Amino-4,5,7,8-tetrahydro-thiazolo[4,5-d]azepin-6-yl)-3-ethyl-2-methyl-5-nitro-3H-pyrimidin-4-one, or

- 5 -

2-Methyl-5-nitro-6-(4,5,7,8-tetrahydro-thiazolo[4,5-d]azepin-6-yl)-3H-pyrimidin-4-one.

Further preferred compounds of formula I in the scope of the present invention are those, in which

- 5 R^1 is hydroxy and
 HET represents a pyrimidine group.

The following are examples of such compounds:

- 7-(6-Hydroxy-2-methyl-5-nitro-pyrimidin-4-yl)-2-methyl-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-ol, or
 10 2-Methyl-5-nitro-6-(5,6,8,9-tetrahydro-pyrimido[4,5-d]azepin-7-yl)-pyrimidin-4-ol.


The term "lower alkyl" used in the present description denotes straight-chain or branched saturated hydrocarbon residues with 1-7 carbon atoms, preferably with 1-4 carbon atoms, such as methyl, ethyl, n-propyl, i-propyl and the like.

- 15 The term "lower alkenyl" used in the present description denotes straight-chain or branched unsaturated hydrocarbon residues with 2-7 carbon atoms, preferably with 2-4 carbon atoms.

The term "lower alkoxy" denotes a lower alkyl residue in the sense of the foregoing definition bonded via an oxygen atom.

- 20 The compounds of general formula I and their pharmaceutically acceptable salts can be manufactured by


a) reacting a compound of the formula




III

with a compound of formula

- 6 -




to a compound of formula




wherein R³ and R⁵ to R¹² have the significance given above.

5 b) reacting a compound of formula




to a compound of formula




or to a compound of formula

- 7 -




wherein R^2 , R^3 and R^5 to R^{12} have the significance given above and R signifies hydrogen or lower alkyl, or

c) reacting a compound of formula




5

with a compound of formula



to a compound of formula



10

wherein the substituents have the significance given above,

and, if desired,


converting a functional group in a compound of formula I into another functional group and, if desired,

converting a compound of formula I into a pharmaceutically acceptable salt.

In the following schemes I to VII and in Examples 1 - 10 the reaction steps and reaction variants a) - c) are described in more detail.


Chloro-methoxy-nitro pyrimidines VII (Scheme I) are known [e.g. 6-chloro-4-methoxy-2-methyl-5-nitro-pyrimidine: Helv. (1958), 41, 1806]. Treatment of the 2-alkyl
 5 6-chloro-4-methoxy-5-nitro-pyrimidines VII with hydrobromic acid in acetic acid preferentially at temperatures between 0 °C and 60 °C gives the 2-alkyl-6-bromo-5-nitro-3H-pyrimidin-4-ones III (Scheme I).

Scheme I



The 2-alkyl-6-bromo-5-nitro-3H-pyrimidin-4-ones III react with optionally substituted secondary amines IV in the presence of a base like triethylamine in solvents like N,N-dimethylformamide, dimethylsulfoxide, acetone, methyl-ethylketone or tetrahydrofuran at temperatures between 0 °C and 100 °C to the tertiary amines I-1 (Scheme II).


Scheme II



Bis(methylthio)-acrylates VIII react with optionally substituted secondary amines IV in the presence of bases like potassium carbonate and/or triethylamine in solvents like ethanol, methanol, acetone or methyl-ethylketone at temperatures between room
 20 temperature and 100 °C to adducts V, which can be formed as Z-isomer, as mixture of E and Z isomers or as E isomer (Scheme III). Adducts V can be reacted with amidines, urea or thiourea derivatives VI either in the presence of 1,8-diazabicyclo[5.4.0]undec-7-ene in N,N-dimethylformamide or dimethylsulfoxide at temperatures between 70 °C and 140 °C or in the presence of sodium ethylate in ethanol preferentially at reflux thus yielding
 25 pyrimidineoles I-2 or pyrimidinones I-3.

- 9 -

Scheme III




Alkylation of adducts I-2 with R² being a cyano or a nitro group (Scheme III) using optionally substituted alkyl halides, tosylates, mesylates or trifluoro-methanesulfonates in solvents like ethanol, methanol, dichloromethane, chloroform, N,N-dimethylformamide, dimethylsulfoxide, acetone, methyl-ethylketone or tetrahydrofuran in the presence of a base like alkali carbonates, e.g. sodium, potassium or cesium carbonate, tertiary amines like triethylamine or ethyl-diisopropylamine, alkali methyl hydrides, like sodium or potassium hydride, or phase transfer catalysts like benzyl-trimethylammonium chloride in the presence of solid or concentrated aqueous sodium hydroxide gives variable mixtures of N- and/ or O-alkylated products I-3 and I-4.

Azepines IV-1 condensed to a heteroaromatic 5-membered ring bearing two heteroatoms can be prepared from bromoazepinones IX (Scheme IV) as e.g. 4-bromo-5-

oxo-azepane-1-carboxylic acid tert.-butyl ester (prepared from 5-bromo-azepan-4-one hydrobromide (1:1) [Ger. Offen. (1989), DE 3820775] with di-tert.-butyldicarbonate in dioxane/aq. sodium hydrogen carbonate solution at room temperature) by reaction with an amide, a thioamide, an urea or a thiourea compound in a solvent like ethanol, dioxane or acetonitrile in the presence of a base like sodium ethylate or triethylamine at temperatures between room temperature and 120 °C followed by removal of the tert.-butoxy carbonyl function with acid, e.g. with hydrogen chloride (aqueous, 37%) in methanol at temperatures between room temperature and 80 °C.

Scheme IV



10

Azepines IV-2 condensed to a heteroaromatic 6-membered ring bearing two heteroatoms can be prepared from alkoxy-carbonyl-azepinones XII as e.g. 4-ethoxy-carbonyl-5-oxo-azepane-1-carboxylic acid tert.-butyl ester [Synthetic Communications 22 (1992), 1249-1258] (Scheme V) by condensation with an amidine XIII in a solvent like ethanol, dioxane or N,N-dimethylformamide in the presence of a base like sodium ethoxide or potassium tert.-butylate at temperatures between 40 °C and 110 °C. The primarily formed compounds XIVa can be further modified by transformation of the hydroxy function into a leaving group, e.g. a trifluorosulfonyloxy function with trifluorosulfonic acid anhydride and a base like triethylamine in an inert solvent like dichloromethane at temperatures between -40 °C and 60 °C, thus giving compounds XIVb. The trifluorosulfonyloxy function in compounds XIVb can then be replaced by a hydrazine moiety by reacting it with hydrazine in a solvent like ethanol preferentially at reflux giving


20

- 11 -

compounds XIVc. Hydrazino-compounds XIVc can be transformed by silver oxide in ethanol at reflux into the compounds XIVd, a sequence as described in [Bull. Chem. Soc. Jap. (1971), 44(1), 153-8]. Removal of the tert.-butoxy carbonyl function in compounds XIVa or XIVd with acid, e.g. with hydrogen chloride (aqueous, 37%) in methanol at

5 temperatures between room temperature and 80 °C gives then the azepines IV-2.

Scheme V



5,6,7,8-Tetrahydro-4H-thieno[2,3-d]azepines IV-3 and IV-5 with or without a hydroxy function at the carbon attached to the thieno moiety are known [J. Heterocyclic

10 Chem. 22, 1011 (1985)]. Precursor acid chlorides XV bearing preferentially a tosyloxy protective function at the azepine secondary nitrogen function are cyclized in an inert solvent like 1,2-dichloroethane, dichloromethane or nitrobenzene in the presence of a Lewis acid catalyst like aluminium trichloride, tin tetrachloride or phosphorous pentachloride at temperatures between -40 °C and 80 °C to yield the protected ketones

15 XVI. Keto thieno[2,3-d]azepines IV-4 are then prepared by cleavage of N-tosyl function with hydrobromic acid in the presence of a scavenger reagent like phenol in a solvent like ethyl acetate at room temperature, whereas hydroxy thieno[2,3-d]azepines IV-3 can be

- 12 -


obtained by simultaneous reduction of the keton function and removal of the N-tosyl protective function by treatment with sodium bis(methoxyethoxy)aluminium-hydride in toluene at reflux. The hydroxy thieno[2,3-d]azepines IV-3 can be further reduced to 5,6,7,8-tetrahydro-4H-thieno[2,3-d]azepines IV-5 with stannous chloride in acetic acid in
5 the presence of hydrochloric acid at temperatures between room temperature and 100 °C.

5,6,7,8-Tetrahydro-4H-thieno[3,4-d]azepines IV-6 isomeric to 5,6,7,8-tetrahydro-4H-thieno[2,3-d]azepines IV-5 can be prepared from 2-thiophen-3-yl-ethylamine derivatives XVII [Eur. Pat. Appl. (1988), EP 274324 A1] in an analogous sequence as described for the thieno[2,3-d]azepines outlined in detail in Scheme VI.

10

Scheme VI


- 13 -



A labeled compound, for example 1-ethyl-2-methyl-6-oxo-4-(1,1,2-tritritio-1,2,4,5-tetrahydro-benzo[d]azepin-3-yl)-1,6-dihydro-pyrimidine-5-carbonitrile, is needed for the binding assay for the characterization of mGluR 1 antagonistic properties and can be prepared according to synthesis schemes I – III starting from a labeled amine as the 1,1,2-tritritio-2,3,4,5-tetrahydro-1H-benzo[d]azepine XXI which can be prepared as outlined in

Scheme VII. The 1-(5-bromo-1,2-dihydro-benzo[d]azepin-3-yl)-ethanone XIX can be obtained by reaction of the 1-(1,2,4,5-tetrahydro-benzo[d]azepin-3-yl)-ethanone XVIII [J. Heterocycl. Chem. (1971), 8(5), 779-83] with N-bromosuccinimide in carbon tetrachloride in the presence of a radical initiator like dibenzoylperoxide or 1,1'-azobis-(cyclohexanecarbonitrile) preferentially at reflux. Hydrogenation of the 1-(5-bromo-1,2-dihydro-benzo[d]azepin-3-yl)-ethanone XIX with tritium gas using a palladium or platinum catalyst in solvents methanol, ethanol or an ether like tetrahydrofuran preferentially in the presence of a base like triethylamine gives the 1-(1,1,2-tritritio-1,2,4,5-tetrahydro-benzo[d]azepin-3-yl)-ethanone XX which can be converted into the 1-(1,1,2-tritritio-1,2,4,5-tetrahydro-benzo[d]azepin-3-yl)-ethanone XXI with conc. aq. hydrochloric acid in methanol.

Scheme VII



The pharmaceutically acceptable salts can be manufactured readily according to methods known per se and taking into consideration the nature of the compound to be converted into a salt. Inorganic or organic acids such as, for example, hydrochloric acid, hydrobromic acid, sulphuric acid, nitric acid, phosphoric acid or citric acid, formic acid, fumaric acid, maleic acid, acetic acid, succinic acid, tartaric acid, methanesulphonic acid, p-toluenesulphonic acid and the like are suitable for the formation of pharmaceutically acceptable salts of basic compounds of formula I. Compounds which contain the alkali metals or alkaline earth metals, for example sodium, potassium, calcium, magnesium or the like, basic amines or basic amino acids are suitable for the formation of pharmaceutically acceptable salts of acidic compounds of formula I.

The compounds of formula I and their pharmaceutically acceptable salts are, as already mentioned above, metabotropic glutamate receptor antagonists and can be used for the treatment or prevention of acute and/or chronic neurological disorders, such as epilepsy, stroke, chronic and acute pain, psychosis, schizophrenia, Alzheimer's disease, cognitive disorders, memory deficits and psychosis. Other treatable indications are restricted brain function caused by bypass operations or transplants, poor blood supply to the brain, spinal cord injuries, head injuries, hypoxia caused by pregnancy, cardiac arrest and hypoglycaemia. Further treatable indications are Huntington's chorea, ALS, dementia caused by AIDS, eye injuries, retinopathy, idiopathic parkinsonism or parkinsonism caused by medicaments as well as conditions which lead to glutamate-deficient functions, such as e.g. muscle spasms, convulsions, migraine, urinary incontinence, nicotine addiction, psychoses, opiate addiction, anxiety, vomiting, dyskinesia and depression.

The compounds of the present invention are group I mGluR antagonists and were tested using the following method:

Binding assay for the characterization of mGluR 1 antagonistic properties

Binding assay with tritiated 1-ethyl-2-methyl-6-oxo-4-(1,1,2-tritritio-1,2,4,5-tetrahydro-benzo[d]azepin-3-yl)-1,6-dihydro-pyrimidine-5-carbonitrile: HEK 293 cells were transiently transfected with the rat mGluR1a receptor. The cells were collected and washed 3 times with PBS. The cell pellets were frozen at -80 °C. Membranes were prepared from HEK 293 cells transfected with the rat mGluR1a receptor and used in the binding experiments at 10 µg proteins per assay after resuspension in a HEPES NaOH 20mM, pH=7.4 binding buffer. 1-Ethyl-2-methyl-6-oxo-4-(1,1,2-tritritio-1,2,4,5-tetrahydro-benzo[d]azepin-3-yl)-1,6-dihydro-pyrimidine-5-carbonitrile (S.A 33.4Ci/mmol) was used at 3 nM final concentration. The incubation with variable concentrations of potential inhibitors was performed for 1 hour at room temperature, the incubate was then filtered onto GF/B glass fiber filter preincubated 1 hour in PEI 0,1% and washed 3 times with 1ml of cold binding buffer. The radioactivity retained on the unifilter 96 was counted using a Topcount β counter. After correction for non specific binding the data were normalized and the IC₅₀ value calculated using a 4 parameters logistic equation which was fitted to the inhibition curve.

Preferred compounds have an IC₅₀ range of 0,001 – 50,00 µM (B-IC₅₀).

In the table below are shown some specific activity data of preferred compounds:

| | Example No. | B-IC ₅₀ (μM) |
|--|-------------|-------------------------|
| 2-methyl-6-(2-methyl-4,5,7,8-tetrahydro-thiazolo[4,5-d]azepin-6-yl)-5-nitro-3H-pyrimidin-4-one | 1 | 30 |
| 6-(6-ethoxy-2-methyl-5-nitro-pyrimidin-4-yl)-2-methyl-5,6,7,8-tetrahydro-4H-thiazolo[4,5-d]azepine | 2 | 4.2 |
| 3-ethyl-2-methyl-6-(2-methyl-4,5,7,8-tetrahydro-thiazolo[4,5-d]azepin-6-yl)-5-nitro-3H-pyrimidin-4-one | 2 | 2.1 |
| 6-(2-amino-4,5,7,8-tetrahydro-thiazolo[4,5-d]azepin-6-yl)-2-methyl-5-nitro-3H-pyrimidin-4-one | 3 | 49 |
| 6-(2-amino-4,5,7,8-tetrahydro-thiazolo[4,5-d]azepin-6-yl)-3-ethyl-2-methyl-5-nitro-3H-pyrimidin-4-one | 4 | 6 |
| 2-methyl-5-nitro-6-(4,5,7,8-tetrahydro-thiazolo[4,5-d]azepin-6-yl)-3H-pyrimidin-4-one | 6 | 43 |
| 2-methyl-5-nitro-6-(4,5,7,8-tetrahydro-thieno[2,3-d]azepin-6-yl)-3H-pyrimidin-4-one | 9 | 1.9 |
| 6-(6-ethoxy-2-methyl-5-nitro-pyrimidin-4-yl)-5,6,7,8-tetrahydro-4H-thieno[2,3-d]azepine | 10 | 0.44 |
| 3-ethyl-2-methyl-5-nitro-6-(4,5,7,8-tetrahydro-thieno[2,3-d]azepin-6-yl)-3H-pyrimidin-4-one | 10 | 0.069 |

The compounds of formula I and pharmaceutically acceptable salts thereof can be used as medicaments, e.g. in the form of pharmaceutical preparations. The pharmaceutical preparations can be administered orally, e.g. in the form of tablets, coated tablets, dragées, hard and soft gelatine capsules, solutions, emulsions or suspensions. However, the administration can also be effected rectally, e.g. in the form of suppositories, or parenterally, e.g. in the form of injection solutions.

The compounds of formula I and pharmaceutically acceptable salts thereof can be processed with pharmaceutically inert, inorganic or organic carriers for the production of pharmaceutical preparations. Lactose, corn starch or derivatives thereof, talc, stearic acid or its salts and the like can be used, for example, as such carriers for tablets, coated tablets, dragées and hard gelatine capsules. Suitable carriers for soft gelatine capsules are, for

example, vegetable oils, waxes, fats, semi-solid and liquid polyols and the like; depending on the nature of the active substance no carriers are, however, usually required in the case of soft gelatine capsules. Suitable carriers for the production of solutions and syrups are, for example, water, polyols, sucrose, invert sugar, glucose and the like. Adjuvants, such as
5 alcohols, polyols, glycerol, vegetable oils and the like, can be used for aqueous injection solutions of water-soluble salts of compounds of formula I, but as a rule are not necessary. Suitable carriers for suppositories are, for example, natural or hardened oils, waxes, fats, semi-liquid or liquid polyols and the like.

In addition, the pharmaceutical preparations can contain preservatives, solubilizers,
10 stabilizers, wetting agents, emulsifiers, sweeteners, colorants, flavorants, salts for varying the osmotic pressure, buffers, masking agents or antioxidants. They can also contain still other therapeutically valuable substances.

As mentioned earlier, medicaments containing a compound of formula I or a pharmaceutically acceptable salt thereof and a therapeutically inert excipient are also an
15 object of the present invention, as is a process for the production of such medicaments which comprises bringing one or more compounds of formula I or pharmaceutically acceptable salts thereof and, if desired, one or more other therapeutically valuable substances into a galenical dosage form together with one or more therapeutically inert carriers.

The dosage can vary within wide limits and will, of course, be fitted to the individual
20 requirements in each particular case. In general, the effective dosage for oral or parenteral administration is between 0.01-20 mg/kg/day, with a dosage of 0.1-10 mg/ kg/day being preferred for all of the indications described. The daily dosage for an adult human being weighing 70 kg accordingly lies between 0.7-1400 mg per day, preferably between 7 and
25 700 mg per day.

Finally, as mentioned earlier, the use of compounds of formula I and of pharmaceutically acceptable salts thereof for the production of medicaments, especially for the control or prevention of acute and/or chronic neurological disorders of the aforementioned kind, is also an object of the invention.

Example 12-Methyl-6-(2-methyl-4,5,7,8-tetrahydro-thiazolo[4,5-d]azepin-6-yl)-5-nitro-3H-pyrimidin-4-onea) 6-Bromo-2-methyl-5-nitro-3H-pyrimidin-4-one

- 5 56.6 ml (503 mmol) of hydrobromic acid solution (48% in water) were added dropwise to a solution of 20.5 g (101 mmol) of the 2-methyl-4-methoxy-5-nitro-6-chloro-pyrimidine [Helv. (1958), 41, 1806] in 450 ml of acetic acid and the reaction mixture was stirred at room temperature for 44 hours. It was then evaporated under reduced pressure and the residue formed poured into 500 ml of an ice/water mixture and extracted 3 times with 500
10 ml of dichloromethane. The combined dichloromethane phases were washed with 100 ml of water and evaporated under reduced pressure. There were thus obtained 16.3 g (69.6 mmol, yield 69%) of the 6-bromo-2-methyl-5-nitro-3H-pyrimidin-4-one as light yellow solid, which was used without further purification.

b) 2-Methyl-5,6,7,8-tetrahydro-4H-thiazolo[4,5-d]azepine

- 15 The title compound was prepared by the following reaction sequence: i) treatment of the 5-bromo-azepan-4-one hydrobromide (1:1) [Ger. Offen. (1989), DE 3820775] with di-*t*-butyldicarbonate in dioxane/aq. sodium hydrogen carbonate solution to yield the 4-bromo-5-oxo-azepane-1-carboxylic acid *tert*-butyl ester; ii) treatment of the 4-bromo-5-oxo-azepane-1-carboxylic acid *tert*-butyl ester with thioacetamide in ethanol in the
20 presence of triethylamine at reflux to give the 2-methyl-4,5,7,8-tetrahydro-thiazolo[4,5-d]azepine-6-carboxylic acid *tert*-butyl ester; iii) conversion of the 2-methyl-4,5,7,8-tetrahydro-thiazolo[4,5-d]azepine-6-carboxylic acid *tert*-butyl ester into the 2-methyl-5,6,7,8-tetrahydro-4H-thiazolo[4,5-d]azepine by removal of the *tert*-butoxycarbonyl function with hydrogen chloride (aqueous, 37%) in methanol at room temperature.

- 25 c) 2-Methyl-6-(2-methyl-4,5,7,8-tetrahydro-thiazolo[4,5-d]azepin-6-yl)-5-nitro-3H-pyrimidin-4-one

- A suspension of 0.234 g (1.00 mmol) of the 6-bromo-2-methyl-5-nitro-3H-pyrimidin-4-one, 0.205 g (1.00 mmol) of the 2-methyl-5,6,7,8-tetrahydro-4H-thiazolo[4,5-d]azepine hydrochloride and 0.304 g (2.20 mmol) of potassium carbonate in 2.0 ml of *N,N*-
30 dimethylformamide was stirred at room temperature for 60 hours. The reaction mixture was then poured into 50 ml of an ice/water mixture and the crystals formed collected by

filtration. Thus, a first crop of the 2-methyl-6-(2-methyl-4,5,7,8-tetrahydro-thiazolo[4,5-d]azepin-6-yl)-5-nitro-3H-pyrimidin-4-one was obtained. The mother liquor was then evaporated and the residue chromatographed on silica gel using a 9:1 v/v mixture of dichloromethane and methanol as eluent giving a second crop of the 2-methyl-6-(2-methyl-4,5,7,8-tetrahydro-thiazolo[4,5-d]azepin-6-yl)-5-nitro-3H-pyrimidin-4-one, in total 0.252 g (0.785 mmol, yield 78.5%) as light yellow solid; m.p. >200 °C; MS: $[M+H]^+ = 322$.

Example 2

6-(6-Ethoxy-2-methyl-5-nitro-pyrimidin-4-yl)-2-methyl-5,6,7,8-tetrahydro-4H-thiazolo[4,5-d]azepine
and
3-Ethyl-2-methyl-6-(2-methyl-4,5,7,8-tetrahydro-thiazolo[4,5-d]azepin-6-yl)-5-nitro-3H-pyrimidin-4-one

A suspension of 0.120 g (0.373 mmol) of 2-methyl-6-(2-methyl-4,5,7,8-tetrahydro-thiazolo[4,5-d]azepin-6-yl)-5-nitro-3H-pyrimidin-4-one (example 1), of 0.070 g (0.45 mmol) of the ethyl iodide and of 0.077 g (0.56 mmol) of potassium carbonate in 1.0 ml of N,N-dimethylformamide was stirred at room temperature for 4 hours. The reaction mixture was then poured into 50 ml of an ice/water mixture and extracted 3 times with 50 ml of ethylacetate. The combined ethylacetate phases were dried over magnesium sulfate and evaporated under reduced pressure. The residue formed was then chromatographed on silica gel using a 95:5 v/v mixture of dichloromethane and methanol as eluent giving in a first fraction 0.025 g (0.072 mmol, yield 19%) of the 6-(6-ethoxy-2-methyl-5-nitro-pyrimidin-4-yl)-2-methyl-5,6,7,8-tetrahydro-4H-thiazolo[4,5-d]azepine as yellow amorphous solid; MS: $[M+H]^+ = 350$.

The second fraction provided 0.081 g (0.23 mmol, yield 62%) of the 3-ethyl-2-methyl-6-(2-methyl-4,5,7,8-tetrahydro-thiazolo[4,5-d]azepin-6-yl)-5-nitro-3H-pyrimidin-4-one as yellow solid after crystallization from ether; m.p. 164.2-166.8 °C; MS: $[M+H]^+ = 350$.

Example 3

6-(2-Amino-4,5,7,8-tetrahydro-thiazolo[4,5-d]azepin-6-yl)-2-methyl-5-nitro-3H-pyrimidin-4-one

In analogy to the procedure described in example 1c 6-bromo-2-methyl-5-nitro-3H-pyrimidin-4-one as prepared in example 1a was treated with 2-amino-5,6,7,8-tetrahydro-4H-thiazolo[4,5-d]azepine [Ger. Offen. (1989), DE 3820775] in N,N-dimethylformamide in the presence of potassium carbonate at 110 °C to yield the title compound as yellow
5 solid; m.p. >200 °C; MS: $[M+H]^+ = 323$.

Example 4

6-(2-Amino-4,5,7,8-tetrahydro-thiazolo[4,5-d]azepin-6-yl)-3-ethyl-2-methyl-5-nitro-3H-pyrimidin-4-one

In analogy to the procedure described in example 2 the 6-(2-amino-4,5,7,8-tetrahydro-
10 thiazolo[4,5-d]azepin-6-yl)-2-methyl-5-nitro-3H-pyrimidin-4-one (example 3) was treated with the ethyl iodide in N,N-dimethylformamide in the presence of potassium carbonate at room temperature to yield the title compound as yellow solid; m.p. >200 °C; MS: $[M+H]^+ = 351$.

Example 5

15 7-(6-Hydroxy-2-methyl-5-nitro-pyrimidin-4-yl)-2-methyl-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-ol

In analogy to the procedure described in example 1c 6-bromo-2-methyl-5-nitro-3H-pyrimidin-4-one (example 1a) was treated with the 2-methyl-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-ol (prepared from the corresponding N-benzyl derivative [Bull.
20 Chem. Soc. Jap. (1971), 44(1), 153-8] by catalytic hydrogenation with palladium on charcoal) in N,N-dimethylformamide in the presence of triethylamine at room temperature to yield the title compound as yellow solid; m.p. >200 °C; MS: $[M+H]^+ = 333$.

Example 6

2-Methyl-5-nitro-6-(4,5,7,8-tetrahydro-thiazolo[4,5-d]azepin-6-yl)-3H-pyrimidin-4-one

25 a) 5,6,7,8-tetrahydro-4H-thiazolo[4,5-d]azepine

The title compound was prepared by the following reaction sequence: i) treatment of 4-bromo-5-oxo-azepane-1-carboxylic acid tert-butyl ester (example 1 b) with phosphorous pentasulfide, formamide and triethylamine in dioxane at reflux to yield 4,5,7,8-tetrahydro-thiazolo[4,5-d]azepine-6-carboxylic acid tert-butyl ester; ii) conversion of 4,5,7,8-

tetrahydro-thiazolo[4,5-d]azepine-6-carboxylic acid tert-butyl ester into 5,6,7,8-tetrahydro-4H-thiazolo[4,5-d]azepine by removal of the tert-butyloxycarbonyl function with hydrogen chloride (aqueous, 37%) in methanol at room temperature.

b) 2-Methyl-5-nitro-6-(4,5,7,8-tetrahydro-thiazolo[4,5-d]azepin-6-yl)-3H-pyrimidin-4-one

In analogy to the procedure described in example 1c 6-bromo-2-methyl-5-nitro-3H-pyrimidin-4-one (example 1a) was treated with the 5,6,7,8-tetrahydro-4H-thiazolo[4,5-d]azepine in N,N-dimethylformamide in the presence of potassium carbonate at room temperature to yield the 2-methyl-5-nitro-6-(4,5,7,8-tetrahydro-thiazolo[4,5-d]azepin-6-yl)-3H-pyrimidin-4-one as yellow amorphous solid; MS: $[M-H]^- = 306$.

Example 7

2-Methyl-5-nitro-6-(5,6,8,9-tetrahydro-pyrimido[4,5-d]azepin-7-yl)-pyrimidin-4-ol

In analogy to the procedure described in example 1c 6-bromo-2-methyl-5-nitro-3H-pyrimidin-4-one (example 1a) was treated with 6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepine trihydrochloride [Bull. Chem. Soc. Jap. (1971), 44(1), 153-8] in N,N-dimethylformamide in the presence of N-ethyl-di-isopropylamine at room temperature to yield the title compound as yellow solid; m.p. $>200^\circ\text{C}$; MS: $[M-H]^- = 301$.

Example 8

[rac]-6-(4-Hydroxy-4,5,7,8-tetrahydro-thieno[2,3-d]azepin-6-yl)-2-methyl-5-nitro-3H-pyrimidin-4-one

In analogy to the procedure described in example 1c 6-bromo-2-methyl-5-nitro-3H-pyrimidin-4-one (example 1a) was treated with the [rac]-5,6,7,8-tetrahydro-4H-thieno[2,3-d]azepin-4-ol [J. Heterocycl. Chem. (1985), 22(4), 1011-16] in N,N-dimethylformamide in the presence of N-ethyl-di-isopropylamine at room temperature to yield the title compound as light yellow oil; MS: $[M-H]^- = 321$.

Example 9

2-Methyl-5-nitro-6-(4,5,7,8-tetrahydro-thieno[2,3-d]azepin-6-yl)-3H-pyrimidin-4-one

- According to the method described in example 1c 6-bromo-2-methyl-5-nitro-3H-pyrimidin-4-one (example 1a) was treated with 5,6,7,8-tetrahydro-4H-thieno[2,3-d]azepine [J. Heterocycl. Chem. (1985), 22(4), 1011-16] in N,N-dimethylformamide in the presence of N-ethyl-di-isopropylamine at room temperature to yield the title compound as
- 5 yellow solid; m.p. >200 °C; MS: $[M-H]^- = 305$.

Example 10

6-(6-Ethoxy-2-methyl-5-nitro-pyrimidin-4-yl)-5,6,7,8-tetrahydro-4H-thieno[2,3-d]azepine

and

- 10 3-Ethyl-2-methyl-5-nitro-6-(4,5,7,8-tetrahydro-thieno[2,3-d]azepin-6-yl)-3H-pyrimidin-4-one

- In analogy to the procedure described in example 2 2-methyl-5-nitro-6-(4,5,7,8-tetrahydro-thieno[2,3-d]azepin-6-yl)-3H-pyrimidin-4-one (example 9) was treated with ethyl bromide in N,N-dimethylformamide in the presence of potassium carbonate at room
- 15 temperature to yield 6-(6-ethoxy-2-methyl-5-nitro-pyrimidin-4-yl)-5,6,7,8-tetrahydro-4H-thieno[2,3-d]azepine as light yellow amorphous solid; MS: $[M+H]^+ = 335$; and 3-ethyl-2-methyl-5-nitro-6-(4,5,7,8-tetrahydro-thieno[2,3-d]azepin-6-yl)-3H-pyrimidin-4-one as yellow foam; MS: $[M+H]^+ = 335$.

Preparation of the labeled compound needed for the binding assay

- 20 1-Ethyl-2-methyl-6-oxo-4-(1,1,2-tritritio-1,2,4,5-tetrahydro-benzo[d]azepin-3-yl)-1,6-dihydro-pyrimidine-5-carbonitrile

a) 1,1,2-Tritritio-2,3,4,5-tetrahydro-1H-benzo[d]azepine

The 1,1,2-tritritio-2,3,4,5-tetrahydro-1H-benzo[d]azepine was obtained by the following sequence:

- 25 i) reaction of the 1-(1,2,4,5-tetrahydro-benzo[d]azepin-3-yl)-ethanone [J. Heterocycl. Chem. (1971), 8(5), 779-83] with dibenzoylperoxide and N-bromosuccinimide in carbon tetrachloride at reflux yielded the 1-(5-bromo-1,2-dihydro-benzo[d]azepin-3-yl)-ethanone;

ii) hydrogenation of the 1-(5-bromo-1,2-dihydro-benzo[d]azepin-3-yl)-ethanone with tritium using Pd/C in methanol in the presence of triethylamine yielded the 1-(1,1,2-tritritio-1,2,4,5-tetrahydro-benzo[d]azepin-3-yl)-ethanone;

iii) treatment of the 1-(1,1,2-tritritio-1,2,4,5-tetrahydro-benzo[d]azepin-3-yl)-ethanone with conc. aq. hydrochloric acid in methanol gave the 1,1,2-tritritio-2,3,4,5-tetrahydro-1H-benzo[d]azepine.

b) E- and/or Z-2-cyano-3-methylsulfanyl-3-(1,1,2-tritritio-1,2,4,5-tetrahydro-benzo[d]azepin-3-yl)-acrylic acid ethyl ester

A solution of 35 mg (0.16 mmol) of ethyl 2-cyano-3,3-bis(methylthio)acrylate, of 4.4 mg (0.024 mmol) of 1,1,2-tritritio-2,3,4,5-tetrahydro-1H-benzo[d]azepine hydrochloride, and of 10 mg (0.1 mmol) of triethylamine in 0.37 ml of ethanol was heated at reflux for 6.5 h. The reaction mixture was then evaporated and the residue chromatographed on 6 g Lichroprep silica gel Si-60 (25-40 μ m) using a 5:1 v/v mixture of toluene and ethyl acetate as eluent. Thus, 4.5 mg (0.014 mmol, yield 60%) of the E- and/or Z- 2-cyano-3-methylsulfanyl-3-(1,1,2-tritritio-1,2,4,5-tetrahydro-benzo[d]azepin-3-yl)-acrylic acid ethyl ester was obtained.

c) 2-methyl-6-oxo-4-(1,1,2-tritritio-1,2,4,5-tetrahydro-benzo[d]azepin-3-yl)-1,6-dihydro-pyrimidine-5-carbonitrile

A solution of 4.4 mg (0.014 mmol) of Z- and/or E-2-cyano-3-methylsulfanyl-3-(1,1,2-tritritio-1,2,4,5-tetrahydro-benzo[d]azepin-3-yl)-acrylic acid ethyl ester, of 3 mg (0.032 mmol) of acetamidine hydrochloride and of 6.6 mg (0.044 mmol) of 1,8-diazabicyclo[5.4.0]undec-7-ene in 1.0 ml of N,N-dimethylformamide was stirred at 100 °C for 2 hours. The reaction mixture was then partitioned between a 50:1 v/v mixture of dichloromethane and methanol and ice water acidified with about 2 ml 0.2 N hydrogen chloride. The organic phase was dried over anhydrous sodium sulfate. The crude product was chromatographed on 5 g Lichroprep silica gel Si-60 (25-40 μ m) using a 6:1 v/v mixture of toluene and methanol as eluent. There was thus obtained 2.2 mg (0.008 mmol, yield 57 %) of 2-methyl-6-oxo-4-(1,1,2-tritritio-1,2,4,5-tetrahydro-benzo[d]azepin-3-yl)-1,6-dihydro-pyrimidine-5-carbonitrile.

d) 1-Ethyl-2-methyl-6-oxo-4-(1,1,2-tritritio-1,2,4,5-tetrahydro-benzo[d]azepin-3-yl)-1,6-dihydro-pyrimidine-5-carbonitrile

A suspension of 2.2 mg (0.008 mmol) of 2-methyl-6-oxo-4-(1,1,2-tritritio-1,2,4,5-tetrahydro-benzo[d]azepin-3-yl)-1,6-dihydro-pyrimidine-5-carbonitrile, of 16 mg (0.10 mmol) of ethyl iodide and of 4.3 mg (0.031 mmol) of potassium carbonate in 0.21 ml of N,N-dimethylformamide was stirred at room temperature for 3 h. The reaction mixture
5 was then partitioned between ethyl acetate and ice water acidified with about 1 ml 0.2 N hydrochloric acid. The organic phase was dried over anhydrous sodium sulfate. The thus obtained crude product was purified by chromatography on 5 g Lichroprep silica gel Si-60 (15-25 μ m) using a 50:1 v/v mixture of dichloromethane and methanol as eluent to yield
1.8 mg (0.0058 mmol, yield 73 %) of the 1-ethyl-2-methyl-6-oxo-4-(1,1,2-tritritio-1,2,4,5-
10 tetrahydro-benzo[d]azepin-3-yl)-1,6-dihydro-pyrimidine-5-carbonitrile as colorless solid, MS: $[M(^3H_0)+H]^+ = 309$ (27%), MS: $[M(^3H_1)+H]^+ = 311$ (38%), MS: $[M(^3H_2)+H]^+ = 313$ (27%), MS: $[M(^3H_3)+H]^+ = 315$ (8%).

- 25 -

Example A

Tablets of the following composition are produced in a conventional manner:

| | mg/Tablet |
|------------------------|-------------------|
| Active ingredient | 100 |
| 5 Powdered lactose | 95 |
| White corn starch | 35 |
| Polyvinylpyrrolidone | 8 |
| Na carboxymethylstarch | 10 |
| Magnesium stearate | 2 |
| 10 | Tablet weight 250 |

Example B

Tablets of the following composition are produced in a conventional manner:

| | mg/Tablet |
|------------------------|-------------------|
| Active ingredient | 200 |
| 15 Powdered lactose | 100 |
| White corn starch | 64 |
| Polyvinylpyrrolidone | 12 |
| Na carboxymethylstarch | 20 |
| Magnesium stearate | 4 |
| 20 | Tablet weight 400 |

- 26 -

Example C

Capsules of the following composition are produced:


| | mg/Capsule |
|----------------------------|------------|
| Active ingredient | 50 |
| 5 Crystalline lactose | 60 |
| Microcrystalline cellulose | 34 |
| Talc | 5 |
| Magnesium stearate | 1 |

Capsule fill weight 150

- 10 The active ingredient having a suitable particle size, the crystalline lactose and the microcrystalline cellulose are homogeneously mixed with one another, sieved and thereafter talc and magnesium stearate are admixed. The final mixture is filled into hard gelatine capsules of suitable size.


Claims

1. Compounds of the general formula




wherein


- 5 R^1 signifies oxygen, hydroxy, lower alkoxy or 2,2,2-trifluoroethoxy;
- R^2 signifies nitro or cyano;
- R^3 signifies hydrogen, lower alkyl, oxygen, lower alkoxy, amino, lower alkyl-
 amino or hydroxy-lower alkyl-amino;
- R^4 signifies hydrogen, lower alkyl, lower alkenyl,
 10 or is absent, if the adjacent nitrogen atom already is the origin of three
 bonds as $-N=$ or $=N-$;
- R^5, R^6, R^9 and R^{10} signify, independently from each other, hydrogen or lower alkyl;




signifies



or





R^7 , R^8 , R^{11} or R^{12} signify, independently from each other, hydrogen, lower alkyl, or hydroxy;

R^{13} and R^{14} signify, independently from each other, hydrogen or lower alkyl;

R^{15} and R^{16} signify, independently from each other, hydrogen or lower alkyl;

5 R^{17} signifies hydrogen, lower alkyl, lower alkoxy, hydroxy or amino;

R^{18} signifies hydrogen or hydroxy;

R^{19} signifies hydrogen, lower alkyl, lower alkoxy, hydroxy or amino;

V signifies NH, S or O; and

the dotted line may be a bond,

10 as well as their pharmaceutically acceptable salts.

2. Compounds of formula I in accordance with claim 1, wherein R^2 is NO_2 , and pharmaceutically acceptable salts thereof.

3. Compounds of formula I in accordance with claims 1 and 2, wherein R^1 is $=\text{O}$ or lower alkoxy and HET represents a thiophene group, and pharmaceutically acceptable salts
15 thereof.

4. Compounds of formula I in accordance with claim 3, which are

[rac]-6-(4-hydroxy-4,5,7,8-tetrahydro-thieno[2,3-d]azepin-6-yl)-2-methyl-5-nitro-3H-pyrimidin-4-one,

2-methyl-5-nitro-6-(4,5,7,8-tetrahydro-thieno[2,3-d]azepin-6-yl)-3H-pyrimidin-4-one,

6-(6-ethoxy-2-methyl-5-nitro-pyrimidin-4-yl)-5,6,7,8-tetrahydro-4H-thieno[2,3-d]azepine, or

5 3-ethyl-2-methyl-5-nitro-6-(4,5,7,8-tetrahydro-thieno[2,3-d]azepin-6-yl)-3H-pyrimidin-4-one.

5. Compounds of formula I in accordance with claims 1 and 2, wherein R¹ is =O or lower alkoxy and HET represents a thiazole group, and pharmaceutically acceptable salts thereof.

10 6. Compounds of formula I in accordance with claim 5, which are

2-methyl-6-(2-methyl-4,5,7,8-tetrahydro-thiazolo[4,5-d]azepin-6-yl)-5-nitro-3H-pyrimidin-4-one,

6-(6-ethoxy-2-methyl-5-nitro-pyrimidin-4-yl)-2-methyl-5,6,7,8-tetrahydro-4H-thiazolo[4,5-d]azepine,

15 3-ethyl-2-methyl-6-(2-methyl-4,5,7,8-tetrahydro-thiazolo[4,5-d]azepin-6-yl)-5-nitro-3H-pyrimidin-4-one,

6-(2-amino-4,5,7,8-tetrahydro-thiazolo[4,5-d]azepin-6-yl)-2-methyl-5-nitro-3H-pyrimidin-4-one,

20 6-(2-amino-4,5,7,8-tetrahydro-thiazolo[4,5-d]azepin-6-yl)-3-ethyl-2-methyl-5-nitro-3H-pyrimidin-4-one, or

2-methyl-5-nitro-6-(4,5,7,8-tetrahydro-thiazolo[4,5-d]azepin-6-yl)-3H-pyrimidin-4-one.

7. Compounds of formula I in accordance with claims 1 and 2, wherein R¹ is hydroxy and HET represents a pyrimidine group, and pharmaceutically acceptable salts thereof.

25 8. Compounds of formula I in accordance with claim 7, which are

7-(6-hydroxy-2-methyl-5-nitro-pyrimidin-4-yl)-2-methyl-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-ol, or

2-methyl-5-nitro-6-(5,6,8,9-tetrahydro-pyrimido[4,5-d]azepin-7-yl)-pyrimidin-4-ol.

9. A medicament comprising a compound of formula I according to any one of claims 1 to 8 as well as pharmaceutically acceptable salts thereof and pharmaceutically acceptable excipients.

5 10. A medicament in accordance with claim 9 for the control or prevention of acute and/or chronic neurological disorders such as epilepsy, stroke, chronic and acute pain, psychosis, schizophrenia, Alzheimer's disease, cognitive disorders, memory deficits, restricted brain function caused by bypass operations or transplants, poor blood supply to the brain, spinal cord injuries, head injuries, hypoxia caused by pregnancy, cardiac arrest,
10 hypoglycaemia, Huntington's chorea, ALS, dementia caused by AIDS, eye injuries, retinopathy, idiopathic parkinsonism or parkinsonism caused by medicaments as well as conditions which lead to glutamate-deficiency functions, such as e.g. muscle spasms, convulsions, migraine, urinary incontinence, nicotine addiction, psychoses, opiate addiction, anxiety, vomiting, dyskinesia and depression.


15 11. Compounds of formula I in accordance with any one of claims 1 to 8 as well as pharmaceutically acceptable salts thereof for use in the control or prevention of illness.

 12. The use of compounds of formula I in accordance with any one of claims 1 to 8 as well as pharmaceutically acceptable salts thereof for the manufacture of a medicament for the control or prevention of acute and/or chronic neurological disorders such as epilepsy,
20 stroke, chronic and acute pain, psychosis, schizophrenia, Alzheimer's disease, cognitive disorders, memory deficits, restricted brain function caused by bypass operations or transplants, poor blood supply to the brain, spinal cord injuries, head injuries, hypoxia caused by pregnancy, cardiac arrest, hypoglycaemia, Huntington's chorea, ALS, dementia caused by AIDS, eye injuries, retinopathy, idiopathic parkinsonism or parkinsonism caused
25 by medicaments as well as conditions which lead to glutamate-deficiency functions, such as e.g. muscle spasms, convulsions, migraine, urinary incontinence, nicotine addiction, psychoses, opiate addiction, anxiety, vomiting, dyskinesia and depression.

 13. A process for the manufacture of compounds according to any one of claims 1 to 8 as well as of pharmaceutically acceptable salts thereof, which process comprises


30 a) reacting a compound of the formula

- 31 -




III

with a compound of formula



IV

to a compound of formula




I-1

5

wherein R^3 and R^5 to R^{12} have the significance given above.


b) reacting a compound of formula




I-2

to a compound of formula

- 32 -




or to a compound of formula




wherein R^2 , R^3 and R^5 to R^{12} have the significance given above and R signifies
5 hydroxy or lower alkyl, or

c) reacting a compound of formula




with a compound of formula



10 to a compound of formula

- 33 -



wherein the substituents have the significance given above,

and, if desired,

converting a functional group in a compound of formula I into another functional group

5 and,

if desired,

converting a compound of formula I into a pharmaceutically acceptable salt.

14. Compounds of formula I in accordance with any one of claims 1 to 8, when
manufactured by a process in accordance with claim 13.

10 15. The invention as herein described.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 01/08186

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07D495/04 C07D513/04 C07D487/04 A61K31/55 A61P25/00
 //(C07D495/04,333:00,223:00),(C07D513/04,277:00,223:00),
 (C07D487/04,239:00,223:00)

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

| Category * | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|------------|--|-----------------------|
| A | US 3 804 849 A (GRISS G ET AL) 16 April 1974 (1974-04-16) column 16, line 47 -column 17, line 75; examples | 1,9-12 |
| A | DE 38 20 775 A (THOMAE GMBH DR K) 21 December 1989 (1989-12-21) cited in the application claims 1,7-10 | 1,9-12 |
| A | US 3 940 395 A (SANTILLI ARTHUR A ET AL) 24 February 1976 (1976-02-24) column 3, line 22 - line 29; example XII | 1,9-12 |
| A | US 3 876 636 A (FAURAN CLAUDE P ET AL) 8 April 1975 (1975-04-08) column 7, line 18 -column 8, line 19; tables | 1,9-12 |

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- * & * document member of the same patent family

Date of the actual completion of the international search

11 December 2001

Date of mailing of the international search report

02/01/2002

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
 Fax: (+31-70) 340-3016

Authorized officer

Hass, C

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 01/08186

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

| Category ° | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|------------|--|-----------------------|
| A | CHEMICAL ABSTRACTS, vol. 105, no. 5, 4 August 1986 (1986-08-04) Columbus, Ohio, US; abstract no. 42679v, page 727; XP002185307 abstract & D FREHEL ET AL: J. HETEROCYCL. CHEM., vol. 22, no. 4, 1985, pages 1011-16, ----- | 1 |
| A | CHEMICAL ABSTRACTS, vol. 74, no. 25, 21 June 1971 (1971-06-21) Columbus, Ohio, US; abstract no. 141677r, page 582; XP002185308 abstract & H YAMAMOTO ET AL: BULL. CHEM. SOC. JAP., vol. 44, no. 1, 1971, pages 153-8, ----- | 1 |
| A | W0 92 07844 A (PFIZER) 14 May 1992 (1992-05-14) page 64, line 8 - line 10; claim 1; examples 126,127,133,134 ----- | 1 |
| A | EP 0 274 324 A (SANOFI SA) 13 July 1988 (1988-07-13) cited in the application ----- | |

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 01/08186

| Patent document cited in search report | | Publication date | Patent family member(s) | Publication date |
|---|---|---------------------|----------------------------|---------------------|
| US 3804849 | A | 16-04-1974 | DE 2040510 A1 | 17-02-1972 |
| | | | DE 2127267 A1 | 14-12-1972 |
| | | | AT 310174 B | 15-08-1973 |
| | | | AT 310179 B | 15-08-1973 |
| | | | AT 310180 B | 15-08-1973 |
| | | | AT 310181 B | 15-08-1973 |
| | | | AT 310764 B | 15-09-1973 |
| | | | AT 310182 B | 15-08-1973 |
| | | | AU 462319 B | 19-06-1975 |
| | | | AU 3241171 A | 22-02-1973 |
| | | | BE 771330 A1 | 14-02-1972 |
| | | | BG 17968 A3 | 05-03-1974 |
| | | | BG 17785 A3 | 25-12-1973 |
| | | | BG 17786 A3 | 25-12-1973 |
| | | | CA 965423 A1 | 01-04-1975 |
| | | | CH 561730 A5 | 15-05-1975 |
| | | | CH 562829 A5 | 13-06-1975 |
| | | | CH 571009 A5 | 31-12-1975 |
| | | | CH 562830 A5 | 13-06-1975 |
| | | | CH 571003 A5 | 31-12-1975 |
| | | | CS 178084 B2 | 31-08-1977 |
| | | | DK 136654 B | 07-11-1977 |
| | | | ES 393881 A1 | 16-09-1973 |
| | | | ES 396451 A1 | 16-05-1974 |
| | | | ES 396452 A1 | 16-05-1974 |
| | | | ES 396453 A1 | 16-05-1974 |
| | | | ES 396454 A1 | 16-05-1974 |
| | | | FI 54925 B | 29-12-1978 |
| | | | FR 2102192 A5 | 07-04-1972 |
| | | | GB 1321509 A | 27-06-1973 |
| | | | HU 162343 B | 29-01-1973 |
| | | | IE 35517 B1 | 03-03-1976 |
| | | | IL 37492 A | 14-03-1974 |
| | | | JP 52046236 B | 22-11-1977 |
| | | | NL 7111176 A ,B, | 16-02-1972 |
| | | | NO 131887 B | 12-05-1975 |
| | | | RO 60635 A1 | 15-10-1976 |
| | | | RO 59127 A1 | 15-02-1976 |
| | | | RO 59322 A1 | 15-02-1976 |
| | | | RO 59129 A1 | 15-01-1976 |
| | | | RO 59925 A1 | 15-08-1976 |
| | | | SE 380529 B | 10-11-1975 |
| | | | SU 442601 A3 | 05-09-1974 |
| | | | SU 461507 A3 | 25-02-1975 |
| | | | SU 503526 A3 | 15-02-1976 |
| | | | SU 461508 A3 | 25-02-1975 |
| | | | SU 474151 A3 | 14-06-1975 |
| | | | US 3907996 A | 23-09-1975 |
| | | | YU 208471 A ,B | 31-12-1979 |
| | | | YU 288178 A ,B | 31-12-1979 |
| DE 3820775 | A | 21-12-1989 | DE 3820775 A1 | 21-12-1989 |
| | | | AT 106082 T | 15-06-1994 |
| | | | AU 617188 B2 | 21-11-1991 |
| | | | AU 3659389 A | 21-12-1989 |
| | | | CA 1337195 A1 | 03-10-1995 |
| | | | DD 284021 A5 | 31-10-1990 |
| | | | DE 58907706 D1 | 30-06-1994 |

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 01/08186

| Patent document cited in search report | | Publication date | Patent family member(s) | Publication date |
|---|---|---------------------|--|--|
| DE 3820775 | A | | DK 301689 A EP 0347766 A2 ES 2057022 T3 FI 892991 A ,B, HU 51630 A2 IE 64661 B1 IL 90650 A JP 2045489 A JP 2776892 B2 KR 130202 B1 NO 176357 B NZ 229637 A PT 90907 A ,B SU 1731061 A3 US 5068325 A ZA 8904636 A | 21-12-1989 27-12-1989 16-10-1994 21-12-1989 28-05-1990 23-08-1995 13-05-1993 15-02-1990 16-07-1998 09-04-1998 12-12-1994 29-01-1991 29-12-1989 30-04-1992 26-11-1991 27-02-1991 |
| US 3940395 | A | 24-02-1976 | NONE | |
| US 3876636 | A | 08-04-1975 | FR 2158081 A1 AU 465951 B AU 4811072 A BE 790287 A1 CA 980775 A1 CH 551418 A DE 2252822 A1 ES 407913 A1 FR 2225154 A2 GB 1339389 A JP 927609 C JP 49005979 A JP 53005677 B LU 66378 A1 NL 7214533 A SE 398349 B SU 490290 A3 ZA 7207579 A | 15-06-1973 09-10-1975 26-04-1974 19-04-1973 30-12-1975 15-07-1974 03-05-1973 16-11-1975 08-11-1974 05-12-1973 13-10-1978 19-01-1974 01-03-1978 03-05-1973 02-05-1973 19-12-1977 30-10-1975 25-07-1973 |
| WO 9207844 | A | 14-05-1992 | AT 124694 T AU 644035 B2 AU 9059291 A BR 9107070 A CA 2095213 A1 CN 1061411 A CZ 9204009 A3 DE 9190155 U1 DE 69111077 D1 DE 69111077 T2 DK 556310 T3 EP 0556310 A1 ES 2074867 T3 FI 932032 A GR 3017122 T3 HU 64533 A2 IE 913854 A1 MX 9101913 A1 NO 931635 A NZ 240476 A | 15-07-1995 02-12-1993 26-05-1992 31-05-1994 07-05-1992 27-05-1992 15-12-1993 07-10-1993 10-08-1995 02-11-1995 21-08-1995 25-08-1993 16-09-1995 05-05-1993 30-11-1995 28-01-1994 22-05-1992 08-07-1992 05-05-1993 27-04-1994 |

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PC I/EP 01/08186

| Patent document cited in search report | Publication date | Patent family member(s) | Publication date |
|---|---------------------|----------------------------|---------------------|
| WO 9207844 | A | PT 99415 A | 30-09-1992 |
| | | SK 400992 A3 | 09-08-1995 |
| | | US 5444062 A | 22-08-1995 |
| | | WO 9207844 A1 | 14-05-1992 |
| | | ZA 9108767 A | 05-05-1993 |
| <hr/> | | | |
| EP 0274324 | A 13-07-1988 | FR 2608607 A1 | 24-06-1988 |
| | | AT 60768 T | 15-02-1991 |
| | | AU 602036 B2 | 27-09-1990 |
| | | AU 8252787 A | 23-06-1988 |
| | | CA 1308729 A1 | 13-10-1992 |
| | | DE 3767993 D1 | 14-03-1991 |
| | | EP 0274324 A1 | 13-07-1988 |
| | | FI 875596 A ,B, | 24-06-1988 |
| | | GR 3001816 T3 | 23-11-1992 |
| | | HU 48616 A2 | 28-06-1989 |
| | | IE 60381 B | 13-07-1994 |
| | | JP 2113339 C | 21-11-1996 |
| | | JP 8032702 B | 29-03-1996 |
| | | JP 63166875 A | 11-07-1988 |
| | | PT 86375 A ,B | 01-01-1988 |
| | | US 4876362 A | 24-10-1989 |
| <hr/> | | | |